In 2002, global estimates of HIV/AIDS cases were 42 million (UNAIDS, 2002). Datamonitor believes that approximately 50% are undiagnosed and untreated - this represents a significant commercial opportunity for the pharma industry.

Key data and epidemiology of the seven major HIV therapeutic markets highlighting untreated 'untapped' population

Overview of the limitations surrounding 'untapping' patient potential discussing issues such as patient presentation, screening and diagnosis

Examination of a number of diagnostic and monitoring tools that vary in terms of ease of use, cost and accuracy

Discussion of comprehensive initiatives for HIV therapeutic companies in both the public and private sector, based on key opinion leader interviews

In all seven of the major HIV therapeutic markets, a significant proportion of the HIV and AIDS patient population 'escapes' diagnosis and subsequent treatment. Companies need to be aware of this significant 'untapped' population in both existing and emergent markets.

Presentation and diagnosis are two key areas that have been identified for HIV therapeutic stakeholders to focus on, especially, in regards to the latter, in light of the growth of the molecular diagnostic market for all areas of infectious diseases.

Pharma companies looking to capture the untreated HIV population need to target both the public and private sectors. Public sector initiatives include partnerships with governments, international bodies and with patients, physicians and advocacy groups. Private sector collaborations, specifically with HIV diagnostic companies, should be nurtured.

Awareness of the sheer volume of the 'untapped' HIV population will confer an advantage to the key players in the HIV therapy and diagnostic sectors.

Provides an insight into the HIV diagnostic and monitoring tools on the market, with a thorough discussion of their limitations and advantages.

Presents comprehensive strategic recommendations with which to reach this untreated 'untapped' market.